{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:52:40Z","timestamp":1791168760826,"version":"4.1.0"},"reference-count":20,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors derived from chromaffin cells that produce catecholamines. The primary treatment for PPGLs is surgical resection, and even in cases with distant metastases, metastasectomy may be considered. Other therapeutic options for distant metastatic disease include radionuclide therapy, such as 131I-metaiodobenzylguanidine (MIBG) and 177Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-(Tyr3)-octreotate (DOTATATE). However, clear evidence is lacking regarding which patients with distant metastases are the best candidates for metastasectomy or radionuclide therapy. Herein, we report a case of a 58-year-old man who underwent resection of a left pheochromocytoma 10 years prior and was admitted for treatment of recurrent metastases to the liver and peritoneum. Sequential 131I-MIBG and 177Lu-DOTATATE therapies were administered, which contributed to disease control and reduction of catecholamine levels but did not achieve a complete response. Subsequently, all metastatic lesions were successfully resected, leading to normalization of catecholamine secretion. This case suggests that metastasectomy may be preferable to radionuclide therapy in carefully selected patients with limited, resectable metastatic disease, despite the presence of distant and multiple metastases. Furthermore, it highlights the importance of periodic reassessment of resectability in patients with distant metastases, even when radionuclide therapy is initially selected, and consideration of metastasectomy once complete resection becomes feasible.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag307","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:35:59Z","timestamp":1790076959000},"source":"Crossref","is-referenced-by-count":0,"title":["A case of metastasectomy following multiple courses of radionuclide therapy for distant metastatic pheochromocytoma"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6296-2890","authenticated-orcid":false,"given":"Naoki","family":"Wada","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2202-175X","authenticated-orcid":false,"given":"Satoshi","family":"Kawata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3635","authenticated-orcid":false,"given":"Yoshinari","family":"Obata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4432-060X","authenticated-orcid":false,"given":"Yoshito","family":"Tomimaru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-8947","authenticated-orcid":false,"given":"Junji","family":"Kozawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]},{"name":"Department of Diabetes Care Medicine, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-9603","authenticated-orcid":false,"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"1","key":"2026100422271097400_luag307-B1","article-title":"Metastatic pheochromocytoma\/paraganglioma overproducing multiple catecholamines","volume":"3","author":"Yoshioka","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"3","key":"2026100422271097400_luag307-B2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2478\/enr-2019-0020","article-title":"Pheochromocytoma","volume":"53","author":"Farrugia","year":"2019","journal-title":"Endocr Regul"},{"issue":"6","key":"2026100422271097400_luag307-B3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026100422271097400_luag307-B4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026100422271097400_luag307-B5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2021.105712","article-title":"Surgical resection for liver metastasis and local recurrence of pheochromocytoma 16 years after primary surgery: a case report","volume":"81","author":"Ohta","year":"2021","journal-title":"Int J Surg Case Rep"},{"issue":"3","key":"2026100422271097400_luag307-B6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5761\/atcs.cr.20-00162","article-title":"Resection of pulmonary metastases 12 years after initial surgery for a benign pheochromocytoma.","volume":"28","author":"Ueda","year":"2022","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"1","key":"2026100422271097400_luag307-B7","article-title":"Complete remission in metastatic pheochromocytoma treated with extensive surgery","volume":"8","author":"Arnas-Leon","year":"2016","journal-title":"Cureus"},{"issue":"5","key":"2026100422271097400_luag307-B8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"11","key":"2026100422271097400_luag307-B9","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026100422271097400_luag307-B10","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026100422271097400_luag307-B11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"\u2018Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis\u2019","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026100422271097400_luag307-B12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12149-021-01699-0","article-title":"An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma","volume":"36","author":"Inaki","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"5","key":"2026100422271097400_luag307-B13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2026100422271097400_luag307-B14","first-page":"110","article-title":"Radiotherapy update (in Japanese)","volume":"39","author":"Mori","year":"2022","journal-title":"Jpn J Endocr Surg"},{"issue":"1","key":"2026100422271097400_luag307-B15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12149-021-01685-6","article-title":"Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy","volume":"36","author":"Hiromasa","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"4","key":"2026100422271097400_luag307-B16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041024","article-title":"Efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas\/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma: a systematic literature review","volume":"11","author":"Hertelendi","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"2026100422271097400_luag307-B17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"issue":"1","key":"2026100422271097400_luag307-B18","doi-asserted-by":"crossref","first-page":"26456","DOI":"10.1038\/s41598-024-75354-9","article-title":"Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution","volume":"14","author":"Ishizaki","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"2026100422271097400_luag307-B19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12328-023-01784-z","article-title":"Repeat hepatectomy for massive liver metastases from pheochromocytoma: a case report","volume":"16","author":"Nakayama","year":"2023","journal-title":"Clin J Gastroenterol"},{"issue":"11","key":"2026100422271097400_luag307-B20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/ERC-21-0230","article-title":"Risk factors for intraoperative complications in pheochromocytomas","volume":"28","author":"Araujo-Castro","year":"2021","journal-title":"Endocr Relat Cancer"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag307\/71579362\/luag307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag307\/71579362\/luag307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:27:18Z","timestamp":1791167238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag307\/8860427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag307","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,25]]},"article-number":"luag307"}}